ATE500830T1 - Behandlung von krebs beim menschen mit et743 - Google Patents

Behandlung von krebs beim menschen mit et743

Info

Publication number
ATE500830T1
ATE500830T1 AT06014005T AT06014005T ATE500830T1 AT E500830 T1 ATE500830 T1 AT E500830T1 AT 06014005 T AT06014005 T AT 06014005T AT 06014005 T AT06014005 T AT 06014005T AT E500830 T1 ATE500830 T1 AT E500830T1
Authority
AT
Austria
Prior art keywords
human cancer
treating human
treating
cancer
human
Prior art date
Application number
AT06014005T
Other languages
German (de)
English (en)
Inventor
Esteban Cvltkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean Louis Misset
Chris Clinical Twelves
Hoff Daniel D Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE500830T1 publication Critical patent/ATE500830T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06014005T 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743 ATE500830T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
ATE500830T1 true ATE500830T1 (de) 2011-03-15

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1716853B9 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN100477993C (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE500830T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE122008000013I1 (enExample)
DK (3) DK1716853T3 (enExample)
ES (2) ES2294756T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1176964T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
HRP20090345T1 (en) * 2004-10-26 2009-08-31 Pharma Mar S.A. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
JP2019504061A (ja) * 2016-02-04 2019-02-14 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
PL4041194T3 (pl) 2020-04-15 2024-09-09 Ever Valinject Gmbh Kompozycja zawierająca trabektedynę i aminokwas
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ES2313154T3 (es) * 1996-11-05 2009-03-01 The Children's Medical Center Corporation Composiciones que comprenden talodimina y dexametasona para el tratamiento de cancer.
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
CZ301083B6 (cs) 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
CN1195514C (zh) * 1998-05-11 2005-04-06 法马马有限公司 海鞘素 743的代谢物
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
DE60111845T2 (de) 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
CA2418320A1 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
US20040108086A1 (en) 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002078678A2 (en) 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20080293725A1 (en) 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
HRP20090345T1 (en) 2004-10-26 2009-08-31 Pharma Mar S.A. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
WO2007134203A2 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
CY1112753T1 (el) 2016-02-10
BG65680B1 (bg) 2009-06-30
DE60030554D1 (de) 2006-10-19
IL146434A0 (en) 2002-07-25
DE60030554T8 (de) 2008-01-10
CY2008007I1 (el) 2009-11-04
NL300337I1 (nl) 2008-05-01
CY1105818T1 (el) 2011-02-02
LU91418I2 (fr) 2008-05-13
AU4597500A (en) 2000-12-05
PT1702618E (pt) 2008-01-11
SI1716853T1 (sl) 2011-10-28
US20070275942A1 (en) 2007-11-29
KR20020019914A (ko) 2002-03-13
EP1176964B8 (en) 2007-10-10
HUS1500001I1 (hu) 2016-08-29
CY2008007I2 (el) 2009-11-04
AU777417B2 (en) 2004-10-14
US8119638B2 (en) 2012-02-21
EP1716853A2 (en) 2006-11-02
DK1176964T3 (da) 2007-01-15
TR200103819T2 (tr) 2002-04-22
DE60036826D1 (de) 2007-11-29
SI1176964T1 (sl) 2007-02-28
NO324564B1 (no) 2007-11-19
CY1107143T1 (el) 2010-07-28
DE60036826T2 (de) 2008-08-28
AU2005200180B2 (en) 2007-12-13
CN1360503A (zh) 2002-07-24
JP2002544231A (ja) 2002-12-24
PL198185B1 (pl) 2008-06-30
DE60045720D1 (de) 2011-04-21
JP2012149095A (ja) 2012-08-09
EP1702618A3 (en) 2006-12-27
NO2008005I2 (enExample) 2010-09-27
DE60030554T2 (de) 2007-09-13
EP1702618A2 (en) 2006-09-20
DK1716853T3 (da) 2011-06-27
ATE375795T1 (de) 2007-11-15
NO20015516D0 (no) 2001-11-12
SK16442001A3 (sk) 2002-03-05
ES2294756T3 (es) 2008-04-01
AU2005200180B9 (en) 2008-05-29
NO20015516L (no) 2002-01-11
PT1176964E (pt) 2007-01-31
AR028476A1 (es) 2003-05-14
WO2000069441A1 (en) 2000-11-23
BR0010531A (pt) 2002-06-04
LU91418I9 (enExample) 2019-01-02
PL352931A1 (en) 2003-09-22
AU2005200180A1 (en) 2005-02-10
JP5777562B2 (ja) 2015-09-09
EP1702618B1 (en) 2007-10-17
SK287580B6 (sk) 2011-03-04
HUP0201187A3 (en) 2002-11-28
CA2373794C (en) 2005-10-11
DE122008000013I1 (de) 2008-08-07
EP1176964B1 (en) 2006-09-06
FR08C0013I1 (enExample) 2008-05-30
ES2272279T3 (es) 2007-05-01
EP1716853A3 (en) 2006-11-15
IL146434A (en) 2008-03-20
HU229866B1 (en) 2014-10-28
EP1176964A1 (en) 2002-02-06
NZ515423A (en) 2004-04-30
PT1716853E (pt) 2011-05-12
HUP0201187A2 (en) 2002-09-28
SI1702618T1 (sl) 2008-02-29
FR08C0013I2 (fr) 2009-10-30
MY164077A (en) 2017-11-30
BG106171A (en) 2002-06-28
CA2373794A1 (en) 2000-11-23
ATE338552T1 (de) 2006-09-15
MXPA01011562A (es) 2002-07-30
CZ20014081A3 (cs) 2002-11-13
CN100477993C (zh) 2009-04-15
NL300337I2 (nl) 2008-09-01
EP1716853B1 (en) 2011-03-09
CN1679631A (zh) 2005-10-12
CZ301482B6 (cs) 2010-03-17
DK1702618T3 (da) 2008-02-25
NO2008005I1 (no) 2008-06-09
UA74782C2 (uk) 2006-02-15
EP1716853B9 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
ATE500830T1 (de) Behandlung von krebs beim menschen mit et743
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
NO983266D0 (no) Distribuert Behandling
ITMI990375A1 (it) Trattamento del cancro co epotiloni
DE69915087D1 (de) Behandlung von textilien
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
DE69718990D1 (de) Behandlungsgerät
FI970990A7 (fi) Syövän toteaminen ja hoito
DE69824227D1 (de) Wärmebehandlungsanlage
FI20000863A0 (fi) Uusi hoitomenetelmä
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
FI972484L (fi) Karsinooman hoito
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
NO20005179D0 (no) Medikament behandling
FI950440L (fi) Elektrodialyysikäsittely
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
DE69807225D1 (de) Vliesstoffbehandlung
FI960658A7 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
NO983263L (no) Distribuert behandling
IS4789A (is) Meðferðarefnasambönd
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
EP1225919A4 (en) TREATMENT OF CANCER
MX9200725A (es) Tratamiento de cancer esofagico. tratamiento de cancer esofagico.